Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Avalo Therapeutics, Inc. (CERC) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
10/03/2023 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11  Interactive Data
08/14/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SECOND FORBEARANCE AGREEMENT"
08/08/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/07/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "AMENDMENT NO. 1 TO SALES AGREEMENT",
"Wyrick Robbins Yates & Ponton LLP 4101 Lake Boone Trail, Suite 300"
08/07/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates"
07/21/2023 8-K Quarterly results
06/29/2023 SC 13G/A Caissa Capital Management ltd. reports a 0% stake in Avalo Therapeutics, Inc.
06/02/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK",
"[SIGNATURE PAGE FOLLOWS&#93"
05/04/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/04/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/04/2023 8-K Quarterly results
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
05/03/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/28/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/25/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
04/21/2023 8-K Quarterly results
04/19/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
03/29/2023 10-K Annual Report for the period ended December 31, 2022
03/29/2023 8-K Quarterly results
03/13/2023 8-K Investor presentation
Docs: "FOR DISCUSSION PURPOSES ONLY Avalo Therapeutics, Inc. March 2023 Corporate Presentation"
02/14/2023 SC 13G/A Nantahala Capital Management, LLC reports a 7% stake in AVALO THERAPEUTICS, INC.
02/14/2023 SC 13G/A Caissa Capital Management ltd. reports a 10.6% stake in Avalo Therapeutics, Inc.
02/13/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/09/2023 SC 13D/A ARMISTICE CAPITAL, LLC reports a 35.4% stake in Avalo Therapeutics, Inc.
02/03/2023 8-K Quarterly results
02/03/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/02/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
01/17/2023 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/07/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy